PI3K Pathway Inhibitors: Better Not Left Alone

Author(s): Ben Markman, Jessica J. Tao, Maurizio Scaltriti

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 5 , 2013

Become EABM
Become Reviewer
Call for Editor


The PI3K/Akt/mTOR signaling pathway plays a key role in diverse physiologic processes. It is also central to many aspects of the malignant process. Genetic phenomena that lead to constitutive pathway activation are common in human cancer; the most relevant are mutations affecting the catalytic subunit of PI3K and loss of function of the PTEN tumor suppressor. These factors have made this important cascade attractive as a potential target for cancer therapeutics. A host of inhibitors are now in various stages of development that target key nodes within the PI3K pathway. To date, however, the efficacy of these agents has fallen short of expectation, with at least one possible explanation being the presence of feedback loops and cross-talk that exists within and between PI3K and other signaling pathways. Accordingly, enthusiasm is again high as strategies employing therapeutic combinations are gaining pace, with encouraging results documented in both preclinical studies and emerging clinical trials. Here, we review the agents that have reached evaluation in early phase clinical studies of human subjects with cancer, and discuss the rationale for and use of novel drug combinations.

Keywords: PI3K, PIK3CA, PTEN, mTOR, Akt, PI3K inhibitor, therapeutic combination, clinical trial, signaling pathway, tumor suppressor

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 10 December, 2012
Page: [895 - 906]
Pages: 12
DOI: 10.2174/1381612811306050895

Article Metrics

PDF: 68